مباشر
FierceBiotechPulnovo Medical scores $100M in finance round led by MedtronicLonza NewsLonza Group AG stock (CH0013841017): Why biopharma contract manufacturing now matters more for U.S. - AD HOC NEWS10x Genomics BlogIs Atera’s New Spatial Biology Platform Altering The Investment Case For 10x Genomics (TXG)? - simplywall.stBrady CorporationMilwaukee’s Brady Corp Buying Honeywell Division - Seehafer NewsFierceBiotechFoundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic targetFierceBiotechIn a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancerFierceBiotechRay Therapeutics shines a light on $125M round targeting genetic eye therapyFierceBiotechTortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from AsiaFierceBiotechPfizer's strategy head Andrew Baum to step down following brief tenure: reportsBioWorldPricing standoff leaves Australian patients in limboBioWorldMabwell turns to Hong Kong to fund ADC ambitionsBioWorldXuanzhu shares dip despite phase III ALK inhibitor data
BioWorld ١٨ مارس ٢٠٢٦

CSPC Zhongqi Pharmaceutical Technology synthesizes PDE4B2 inhibitors

CSPC Zhongqi Pharmaceutical Technology synthesizes PDE4B2 inhibitors

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.